Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.
- First commercial sales from ColoSTAT and geneType
- FY2026 sales revenue of $85,339 against a $5.93 million loss
- Operating cash outflow increased to $5.23 million
- Cash balance rose to $3.36 million after funding activity
- Auditor highlighted material uncertainty around going concern
Commercial launch arrives before commercial scale
Rhythm Biosciences Limited (ASX:RHY) has crossed an important threshold, but not yet the one that matters most to its balance sheet. The cancer diagnostics company recorded its first commercial sales from both ColoSTAT® and geneType™ during FY2026, marking its shift from development work into early commercialisation.
The financial evidence remains modest. Sales revenue was $85,339 for the year ended 30 June 2026, while total income reached $1.74 million largely because it included a $1.58 million research and development tax refund and $76,442 of interest income. Rhythm reported a loss after tax of $5.93 million, widening from $3.83 million a year earlier, as employment, commercialisation and operating costs increased.
The distinction between product sales and other income is central to the story. Rhythm now has paying customers and commercial infrastructure, but the products have not yet generated revenue remotely sufficient to fund the business.
ColoSTAT gains accreditation, supply and collection access
ColoSTAT advanced through several of the technical and operational gates that had defined the company’s development risk. Rhythm completed clinical validation, updated its laboratory accreditation to ISO 15189:2022, and received NATA accreditation for the ColoSTAT clinical testing service in March 2026. The company also reported 91% sensitivity across colorectal cancer stages I to IV in its final validation.
A manufacturing agreement with Quansys was secured in February, while the 4Cyte Pathology arrangement created a growing network of patient collection sites across Australia’s eastern states. Rhythm said more than 100 4Cyte blood collection sites were available by 30 June. An NHS England evaluation also commenced, although the report does not provide an outcome or a timetable for adoption.
Those milestones reduce some of the scientific, regulatory, manufacturing and access questions surrounding ColoSTAT. They do not answer the commercial questions. Rhythm says it now needs to track reported tests, ordering clinicians, repeat orders, throughput, cost per test and gross margin as the business develops.
Cash improved through funding, not operations
Cash and cash equivalents rose to $3.36 million from $1.40 million, but operating activities consumed $5.23 million during the year, compared with $2.92 million in FY2025. Financing inflows, including proceeds from share and option issues, supplied $7.22 million of net cash, while the company also received a $1.58 million R&D tax refund.
The auditor drew attention to a material uncertainty related to going concern, citing the annual loss and operating cash outflow. The audit opinion was not modified, and the directors said they expect the group to maintain a positive cash position for at least 12 months based on cash on hand, an expected FY2026 R&D refund, potential funding and the ability to reduce expenditure if required. That outlook remains dependent on events that are not guaranteed, particularly future capital access and the pace of commercial adoption.
FY2027 shifts the burden to adoption and reimbursement
Rhythm’s geneType platform added a Southeast Asian clinical sale, a US platform partnership with Cancer IQ and a scale-up partnership with the Australian Genome Research Facility. The company also launched an enhanced colorectal cancer risk assessment test, which management positions as complementary to ColoSTAT’s role in deciding which symptomatic patients may require further investigation.
For FY2027, however, the company identifies reimbursement, clinician behaviour, international expansion and spending discipline as the main challenges. It says reimbursement applications in Australia and the United States are multi-year processes with no guaranteed result. The report also records a planned lung cancer blood-based assay prototype, but that remains an early development opportunity rather than a current revenue stream.
Rhythm has therefore exchanged one set of risks for another. The question is no longer only whether the technology can be validated and supplied; it is whether enough clinicians order it repeatedly, whether patients can access it conveniently and whether the resulting economics can support the cash required to reach scale.
Bottom Line?
The commercial milestone is real, but the next decisive evidence will be recurring test volumes, product revenue and cash discipline before funding becomes the dominant story again.
Questions in the middle?
- How quickly can ColoSTAT sales grow beyond the initial $85,339 revenue base?
- Will reimbursement or other market-access pathways emerge before the company needs further capital?
- Can repeat clinician ordering and gross margins improve quickly enough to reduce reliance on R&D refunds and funding markets?